What We're Reading: Page 172
Industry reads hand-picked by our editors
Oct 21, 2020
-
The New York Times
Antibody Treatments, Though Promising, Will Be in Short Supply
-
Endpoints News
SparingVision raises $52M to kick off long journey for a next-gen gene therapy that goes much, much broader than Luxturna
-
Science
Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus?
Oct 20, 2020
-
The New York Times
Volunteers to Be Infected With Coronavirus in Vaccine Study
-
Endpoints News
Super-secretive anti-aging biotech Calico tees up the first visible clinical trial of an experimental drug. And it’s for cancer?
-
The Wall Street Journal
China Drugmaker Gives Unproven Covid-19 Vaccine to Students Going Abroad
-
Future Human
A Startup Is Making Thousands of Gene-Edited Pigs Because Humans Need Their Organs
Oct 19, 2020
-
C&EN
The curious DNA circles that make treating cancer so hard
-
BioCentury
Christie's COVID-19 treatment raises fairness, safety questions
-
FierceBiotech
The top 10 takeover targets in biopharma
-
The Wall Street Journal
Where Do I Go to Get My Covid Antibody Cocktail?
Oct 16, 2020
-
The Wall Street Journal
NIH to Study Three Drugs in Treatment of Covid-19 Patients
-
FierceBiotech
Galapagos' osteoarthritis drug flunks Phase 2, dashing hopes of $250M Gilead deal
-
S&P Global
Trump ally Chris Christie among the few to get Lilly COVID-19 antibody drug
-
The New York Times
U.S. Investigates Vaxart's Claims Related to Covid-19 Vaccine
Oct 15, 2020
-
Bloomberg
FDA Chief Defends Vaccine-Trial Halts as Vital to Safety System
-
Endpoints News
Patient death in pivotal gene therapy trial rattles Sarepta partner already facing clinical hold
-
Future Human
Fresh Off Her Nobel Prize Win, Jennifer Doudna Predicts What’s Next for CRISPR
-
LifeSciVC
It’s Raining Biotech SPACs!
Oct 14, 2020
-
Reuters
FDA faults quality control at Lilly plant making Trump-touted COVID drug
-
STAT
Selling stock at a clip, top Moderna doctor gets $1 million richer each week
-
FierceBiotech
Cyclerion fails sickle cell test, prompting pivot to CNS disease
-
Politico
FDA pushes back on Trump administration attempt to rebrand 'emergency authorization'
Oct 13, 2020
-
The New York Times
The Race for a Super-Antibody Against the Coronavirus
-
STAT
How would doctors and insurers navigate demand for a new, narrow Alzheimer's drug?
-
In the Pipeline
Another Vaccine Trial Halt
Previous
